SUPER RNAi™ - The integrated RNA interference sytem
Methods have been established that achieve stable long-term RNAi in all types of mammalian cells, including oocytes, embryonic stem cells and fully differentiated somatic cells. This system includes the pSUPER vector which allows the stable, long-term expression of siRNAs in eukaryotic cells in a rapid and inexpensive manner, and access to CRT’s patent on methods of performing RNAi in mammalian cells, for both short-term and longer-term loss-of-function genomic analysis in target validation and drug discovery and development.
Contact: Dr Nick Gower, ngower@CancerTechnology.com
 Further details can be accessed here
DamID: Mapping Protein-Genome Interactions
DamID is a powerful method that allows the identification of the in vivo genomic binding sites of proteins that regulate gene expression, DNA replication, and chromatin structure. DamID can be used as an efficient large-scale mapping technology and has many advantages over commonly used alternatives such as chIP-chip based methods
Contact: Dr Nick Gower, ngower@CancerTechnology.com
Further details can be accessed here
Novel Marker of Early ES Cell Differentiation
A novel cell surface marker that is able to determine both the pluripotency and early differentiation state of an ES cell population in a single, rapid, non-destructive assay. This marker is a valuable tool for a wide range of ES cell techniques. Well characterised monoclonal antibodies to mouse and human antigens are available.
Contact: Dr Tanya Moore, tmoore@CancerTechnology.com
Further details can be accessed here
Endothelial Tissue-specific and Inducible Cre Transgenic Mice (New)
Inducible Cre transgenic strains expressing the Cre-ER(T2) gene switch under the control of VECAD or BMX promoters. These mice can be crossed with mice carrying LoxP-flanked genes of interest to generate temporally controlled tissue-specific deletions upon tamoxifen treatment. Tamoxifen treatment of the VECAD-Cre-ER(T2) embryos induces Cre activity in >90% of endothelial cells of all arteries, veins and in the lymphatic system. Tamoxifen treatment of adult mice induces Cre activity only in smaller vascular beds. These mice may be used for study of genes involved in vascular development and pathological angiogenesis in adult mice. Tamoxifen treatment of the BMX-Cre-ER(T2) mice induces Cre activity in arterial but not venous endothelial cells. These mice may be useful for study of genes involved in pathological arterial conditions, including artherosclerosis.
Contact: Dr Laura Fletcher, lfletcher@CancerTechnology.com
Further details can be accessed here
Microorganism Detection and Profiling
A new genomic tool for rapid, high throughput, accurate and cost effective identification of microorganisms has been developed. The technology is independent of culture techniques and facilitates the identification of pathogenic organisms in complex biological samples and environmental isolates. The invention also enables the identification of novel organisms and differentiates between closely related bacterial species and strains.
Contact: Dr Adrian Ibrahim, aibrahim@CancerTechnology.com
Transposon Mediated Genomic DNA Integration
Non-exclusive rights are available to a technology enabling the integration of DNA into host genomes across a variety of species, using transposons from the Tc1/Mariner family derived from Drosophila and C. elegans. Applications include gene therapy including stem cell research, gene tagging and genotype/phenotype analysis.
Contact: Dr Anne Horgan, ahorgan@CancerTechnology.com
pBabe
High Titre Retroviral Vectors and Helper-free Packaging Cell
Line
The pBabe series of vectors represent a highly efficient retroviral based gene transfer system for stable expression within mammalian cells. They are derived from the Moloney murine leukemia virus (MMLV) and can be used to produce high titre viral stocks. A helper-free packaging cell line is also available.
Contact: Reagents@CancerTechnology.com
Further details can be accessed here
CyMap: A Novel Miniature Cell Imaging Device
‘CyMap’ is a novel CCD-based cell imaging system with potential applications in automating a wide-range of live cell-based assays. The simple system utilises only low-cost components, is readily miniaturised and can be used inside a standard tissue culture incubator. Furthermore, the imaging modality has great potential for incorporation into lab-on-a-chip devices and integration with microfluidic platforms. The device can be used to monitor a wide range of cellular assays including cell number, cell division, colony formation, wound healing and migration. A patent application covering the CyMap technology has been filed and an exclusive multi-territory license is available to further develop and commercialise the technology.
Contact: Dr Laura Fletcher, lfletcher@CancerTechnology.com
Further details can be accessed here
TIRF: Microscope Test Slide
A test slide for Total Internal Reflection Fluorescence (TIRF) microscopes has been developed which mimics the features of a typical biological sample. It is anticipated that the test slide will find utility in such tasks as comparison of performance between different imaging systems, performance optimisation of a newly installed system, and the long term quality control of system performance.
Contact: Dr Phil Masterson pmasterson@CancerTechnology.com
Further details can be accessed here
Transgenic Mice and Cell Lines
CRT has a portfolio of transgenic mice encompassing conditional knock-ins and knock-outs and animal models derived from these sources. Noteworthy examples include two independent psoriasis models, BRCA1 and BRCA2 breast cancer models and a metastatic breast cancer model. A portfolio of these cell lines is also available for licensing, including TR146, a cell line that represents a unique in vitro model of human buccal mucosa. Copies of the Transgenic Mice and Cell Lines catalogue are available online.
Contact: Reagents@CancerTechnology.com
Antibody Portfolio
CRT's antibody portfolio currently consists of over 450 antibodies. Hybridomas are available for licensing in the fileds of research and in vitro diagnostics, and purified antibody is supplied for research purposes on a sales basis. Copies of the antibody portfolio are available both on request and online in a searchable format, providing a full technical profile for each antibody. Click here for the online version.
Contact: Reagents@CancerTechnology.com
|
